Literature DB >> 9610886

Orphanin FQ/nociceptin: a role in pain and analgesia, but so much more.

T Darland1, M M Heinricher, D K Grandy.   

Abstract

The publication of the delta opioid receptor sequence led to the cloning of three homologous receptors: the mu and kappa opioid receptors, and a novel opioid-like orphan receptor. The orphan receptor's endogenous ligand, a 17-amino-acid peptide that resembles dynorphin, was named 'orphanin FQ' and 'nociceptin' (OFQ/N1-17). The OFQ/N1-17 receptor is expressed widely in the nervous system, and it is becoming clear that the peptide is likely to participate in a broad range of physiological and behavioral functions. At the cellular level, OFQ/N1-17 has much in common with the classical opioids; however, functional studies are now revealing distinct actions of this peptide. Identified only two years ago, OFQ/N1-17 has already attracted a great deal of attention. The number and diversity of papers focused on OFQ/N1-17 at the recent meeting of the Society for Neuroscience augur an exciting future for this new peptide.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9610886     DOI: 10.1016/s0166-2236(97)01204-6

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  49 in total

1.  Orphanin-FQ/nociceptin (OFQ/N) modulates the activity of suprachiasmatic nucleus neurons.

Authors:  C N Allen; Z G Jiang; K Teshima; T Darland; M Ikeda; C S Nelson; D I Quigley; T Yoshioka; R G Allen; M A Rea; D K Grandy
Journal:  J Neurosci       Date:  1999-03-15       Impact factor: 6.167

2.  [Nphe(1)]-Nociceptin (1-13)-NH(2), a nociceptin receptor antagonist, reverses nociceptin-induced spatial memory impairments in the Morris water maze task in rats.

Authors:  J P Redrobe; G Calo; R Guerrini; D Regoli; R Quirion
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

Review 3.  Visualizing activation of opioid circuits by internalization of G protein-coupled receptors.

Authors:  Kevin Sinchak; Paul Micevych
Journal:  Mol Neurobiol       Date:  2003-04       Impact factor: 5.590

Review 4.  Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia.

Authors:  Mark R Hutchinson; Yehuda Shavit; Peter M Grace; Kenner C Rice; Steven F Maier; Linda R Watkins
Journal:  Pharmacol Rev       Date:  2011-07-13       Impact factor: 25.468

5.  Effects of nociceptin and nocistatin on antidromic vasodilatation in hairless skin of the rat hindlimb in vivo.

Authors:  H Häbler; L Timmermann; J Stegmann; W Jänig
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

6.  Nociceptin produces antinociception after spinal administration in amphibians.

Authors:  Craig W Stevens; Kristin K Martin; Brad W Stahlheber
Journal:  Pharmacol Biochem Behav       Date:  2008-09-05       Impact factor: 3.533

7.  Endogenous nociceptin/orphanin-FQ in the dorsal hippocampus facilitates despair-related behavior.

Authors:  Celia Goeldner; David Reiss; Brigitte L Kieffer; Abdel-Mouttalib Ouagazzal
Journal:  Hippocampus       Date:  2010-08       Impact factor: 3.899

8.  Genetic Deletion of the Nociceptin/Orphanin FQ Receptor in the Rat Confers Resilience to the Development of Drug Addiction.

Authors:  Marsida Kallupi; Giulia Scuppa; Giordano de Guglielmo; Girolamo Calò; Friedbert Weiss; Michael A Statnick; Linda M Rorick-Kehn; Roberto Ciccocioppo
Journal:  Neuropsychopharmacology       Date:  2016-08-26       Impact factor: 7.853

9.  Biostable aptamers with antagonistic properties to the neuropeptide nociceptin/orphanin FQ.

Authors:  Dirk Faulhammer; Bernd Eschgfäller; Sandra Stark; Petra Burgstaller; Werner Englberger; Jeannette Erfurth; Frank Kleinjung; Johanna Rupp; Sebastian Dan Vulcu; Werner Schröder; Stefan Vonhoff; Hermann Nawrath; Clemens Gillen; Sven Klussmann
Journal:  RNA       Date:  2004-03       Impact factor: 4.942

10.  Actions of orphanin FQ/nociceptin on rat ventral tegmental area neurons in vitro.

Authors:  Fang Zheng; David K Grandy; Steven W Johnson
Journal:  Br J Pharmacol       Date:  2002-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.